Search research articles
Contact Us
Filters
Showing results (71-80 of 84) with videos related to
Page
of 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2022
Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250-259]
Arndt Stahler, Sebastian Stintzing, Jobst C von Einem, et al.
The Lancet. Oncology
|
October 18, 2015
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial
Christophe Tournigand, Benoist Chibaudel, Benoit Samson, et al.
International Journal of Cancer
|
December 30, 2016
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306)
Dominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 9, 2008
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Alberto F Sobrero, Joan Maurel, Louis Fehrenbacher, et al.
Oncotarget
|
November 9, 2017
Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients
Noemi Pavo, Markus Raderer, Georg Goliasch, et al.
International Journal of Cancer
|
August 25, 2021
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)
Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, et al.
The Lancet. Oncology
|
August 31, 2016
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Sebastian Stintzing, Dominik P Modest, Lisa Rossius, et al.
The New England Journal of Medicine
|
July 1, 2005
Capecitabine as adjuvant treatment for stage III colon cancer
Chris Twelves, Alfred Wong, Marek P Nowacki, et al.
BMC Cancer
|
December 13, 2006
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
Helmut Friess, Jan M Langrehr, Helmut Oettle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
Thierry André, Armand de Gramont, Dewi Vernerey, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 84) with videos related to
Sort By:
Page
of 9
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2022
Corrigendum to 'Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial'. [European Journal of Cancer 137 (2020) 250-259]
Arndt Stahler, Sebastian Stintzing, Jobst C von Einem, et al.
The Lancet. Oncology
|
October 18, 2015
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial
Christophe Tournigand, Benoist Chibaudel, Benoit Samson, et al.
International Journal of Cancer
|
December 30, 2016
Relation of early tumor shrinkage (ETS) observed in first-line treatment to efficacy parameters of subsequent treatment in FIRE-3 (AIOKRK0306)
Dominik P Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 9, 2008
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Alberto F Sobrero, Joan Maurel, Louis Fehrenbacher, et al.
Oncotarget
|
November 9, 2017
Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients
Noemi Pavo, Markus Raderer, Georg Goliasch, et al.
International Journal of Cancer
|
August 25, 2021
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306)
Lian Liu, Nicole Tonya Erickson, Ingrid Ricard, et al.
The Lancet. Oncology
|
August 31, 2016
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Sebastian Stintzing, Dominik P Modest, Lisa Rossius, et al.
The New England Journal of Medicine
|
July 1, 2005
Capecitabine as adjuvant treatment for stage III colon cancer
Chris Twelves, Alfred Wong, Marek P Nowacki, et al.
BMC Cancer
|
December 13, 2006
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
Helmut Friess, Jan M Langrehr, Helmut Oettle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 4, 2015
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
Thierry André, Armand de Gramont, Dewi Vernerey, et al.
Page
of 9